

CONNECT FOR THE CURE
Eastern Ontario Cancer Innovation Forum

MARCH 11, 2010
The Sheraton Ottawa, O'Connor Room

- 8:30 am – 9:30 am** **Registration, Continental Breakfast & Networking**
- 9:30 am – 9:45 am** **Introduction and Welcome Remarks**
Dr. Mona Nemer, VP Research, University of Ottawa
- 9:45 am – 11:15 am** **Research and Development Panel**
- Dr. Michael McBurney**, Depts. of Medicine; Biochemistry, Microbiology & Immunology, University of Ottawa; Director-Cancer Therapeutics, Ottawa Health Research Institute
- Dr. Jeremy Squire**, Depts. of Pathology & Molecular Medicine, Queen's University, Director of Translational Laboratory Research, Queen's Cancer Research Institute
- Has the cancer system become more effective in the last 20 years?**
Dr. Hugh Walker, Depts. of Oncology, Community Health & Epidemiology, Queen's University and President of Walker Economics
- Dr. Giora Feuerstein**, Assistant VP & Head of Discovery Translational Medicine, Wyeth-Pfizer
- 11:15 am – 12:15 pm** **Morning Plenary – Opportunities in Innovation I**
- The development of oncolytic virus therapeutics**
Dr. John Bell , Depts. of Medicine; Biochemistry, Microbiology, Immunology, University of Ottawa, Senior Scientist, Ottawa Health Research Institute and CSO of Jennerex Biotherapeutics
- A high throughput pharmaco-viral approach identifies novel virus sensitizers**
Jean-Simon Diallo, Post-doctoral fellow, University of Ottawa
- Targeting the inhibitors of apoptosis (IAPs) for cancer therapy**
Eric LaCasse, Senior Research Associate, CHEO Research Institute
- ArcticDx and the pull of the market**
Brent Zanke, Dept. of Medicine, University of Ottawa, Scientist, Ottawa Health Research Institute and CMO of ArcticDx
- 12:15 pm – 1:00 pm** **Buffet Luncheon (Poster viewing available on Mezzanine Level)**
- 1:00 pm – 1:45 pm** **Keynote Speaker**
Paul Juniewicz, VP Global Access to External Innovation, Sanofi-Aventis

1:45 pm – 2:45 pm

Afternoon Plenary – Opportunities in Innovation II

RNA interference in malignant melanoma

Victor Tron, Head, Dept. of Pathology & Molecular Medicine, Queen's University

Discovery and validation of novel targeted RET-Kinase inhibitor

Lois Mulligan, Dept. of Pathology & Molecular Medicine, Queen's University

Development of integrative molecular profiling capabilities in ovarian cancer chemoresistance

Harriet Feilotter, Dept. of Pathology & Molecular Medicine, Queen's University

The prognosis of follicular lymphoma with novel biomarker signatures

Tara Baetz, Dept. of Medicine, Queen's University

2:45 pm – 3:45 pm

Expert Panel and Round Table

Startups, Clinical Trials – Made in Canada

Graeme McRae, CEO, BioNiche Life Sciences

Chris Harder, Research & Development Manager, Spartan Bioscience

Janet Dancey, Director, High Impact Clinical Trials, Ontario Institute of Cancer Research

Ken Evans, Director, Ontario Cancer Biomarker Network

Michelle Scarborough, VP Investment & Commercialization, OCRI

3:30 pm – 5:30 pm

BioPartnering / Poster Viewing / Wine and Cheese Networking Reception

Mezzanine Level